Physician profile
Harsh B Jain
NPI 1144365453
$11,883.94
in general payments reported to CMS, 2019-2025
21 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,700 · 2020: $2,948 · 2021: $2,341 · 2022: $538 · 2023: $619 · 2024: $1,171 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.67 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,242.62 | 2019-2025 | Sapien 3 Ultra Resilia, Inspiris Resilia Aortic Valve, Mitris Resilia Mitral Valve |
| Abbott Laboratories | $2,079.03 | 2019-2021 | |
| Atricure, INC. | $1,695.02 | 2021-2025 | Epi-Ease Epicardial Access System |
| Abiomed | $1,341.57 | 2019-2025 | Impella |
| Ethicon INC. | $1,125.00 | 2020 | |
| Medtronic Vascular, INC. | $486.49 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $424.54 | 2020-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $260.88 | 2024 | Camzyos, Eliquis |
| Medtronic, INC. | $209.93 | 2021-2025 | Corevalve Evolut R |
| Kestra Medical Technology Services, INC. | $162.77 | 2022-2025 | Assure Wcd |
| Davol INC. | $150.00 | 2023 | |
| Amgen INC. | $120.84 | 2024 | Repatha |
| Inari Medical, INC. | $115.46 | 2021 | |
| Ethicon US, LLC | $103.45 | 2020 | |
| Baxter Healthcare | $100.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $96.41 | 2024-2025 | |
| Getinge USA Sales, LLC | $52.15 | 2021-2022 | |
| Cvrx, INC. | $42.71 | 2024 | Barostim Neo System |
| Terumo Cardiovascular Systems Corporation | $32.51 | 2025 | Cdi Blood Parameter Monitoring System 550, Terumo Advanced Perfusion System 1 |
| Livanova USA, INC. | $28.37 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.19 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.